Physician profile
Melissa E Skiadas
NPI 1528290061
$2,690.18
in general payments reported to CMS, 2019-2025
18 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.67 · 2022: $52.92 · 2023: $565 · 2024: $1,752 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $382.44 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $362.90 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $272.66 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $218.33 | 2023-2025 | |
| Abbott Laboratories | $151.21 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $136.34 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $118.39 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $109.36 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $80.67 | 2024 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $73.05 | 2024 | Eliquis |
| Inspire Medical Systems, INC. | $47.22 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $41.77 | 2024 | Gemtesa |
| Daiichi Sankyo INC. | $25.00 | 2024 | Injectafer |
| Lundbeck LLC | $18.34 | 2024 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $18.25 | 2024 | Xtampza |
| Idorsia Pharmaceuticals US INC | $16.96 | 2023 | Quviviq |
| Corium, LLC | $13.69 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Skiadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.